Although combined CDK4/6i and endocrine therapy has significantly improved outcome of patients with advanced ER+ breast cancer, progression is expected and thus new therapeutic strategies to overcome treatment resistance are urgently needed. Here, CDK4 is linked to breast carcinoma.